Results 291 to 300 of about 786,143 (326)
Some of the next articles are maybe not open access.
Meningococcal polysaccharide vaccines: A review
Carbohydrate Polymers, 2009Polysaccharides produced by Neisseria meningitidis are pharmaceutically important molecules, and are the active components of vaccines against N. meningitidis serogroups A, C, W135 and Y. Effective vaccines based on capsular polysaccharide, polysaccharide conjugates and outer membrane vesicles have been developed for strains expressing capsular ...
V. Joshi +4 more
semanticscholar +3 more sources
Vaccine, 2007
Asplenic children are at high risk of invasive pneumococcal infection. In this group, the American Academy of Pediatrics recommends a single revaccination with the 23-valent polysaccharide vaccine (PSV23) 3-5 years after a previous PSV23 dose. Despite potential advantages, there are few data available regarding the safety and immunogenicity of the ...
Françoise Smets +6 more
openaire +3 more sources
Asplenic children are at high risk of invasive pneumococcal infection. In this group, the American Academy of Pediatrics recommends a single revaccination with the 23-valent polysaccharide vaccine (PSV23) 3-5 years after a previous PSV23 dose. Despite potential advantages, there are few data available regarding the safety and immunogenicity of the ...
Françoise Smets +6 more
openaire +3 more sources
Immune Response of human infants of polysaccharide vaccines of group A and C Neisseria meningitidis.
Journal of Infectious Diseases, 1977Immunization of infants three to 24 months of age with polysaccharide vaccines derived from groups A and C Neisseria meningitidis induced no significant local or systemic adverse reactions.
R. Gold +3 more
semanticscholar +1 more source
The Pediatric Infectious Disease Journal, 1996
BACKGROUND Streptococcus pneumoniae is the most common cause of invasive bacterial disease and otitis media in infants and young children. Licensed pneumococcal polysaccharide vaccines are not reliably immunogenic in children younger than 2 years of age;
K. O'Brien +5 more
semanticscholar +1 more source
BACKGROUND Streptococcus pneumoniae is the most common cause of invasive bacterial disease and otitis media in infants and young children. Licensed pneumococcal polysaccharide vaccines are not reliably immunogenic in children younger than 2 years of age;
K. O'Brien +5 more
semanticscholar +1 more source
Antiidiotype Antibodies As Surrogates for Polysaccharide Vaccines
Annals of the New York Academy of Sciences, 1994In past studies we demonstrated that monoclonal antibody 6F9 is a surrogate image of the meningococcal C capsular polysaccharide. These studies indicated that immunization with this anti-id resulted in a T-dependent antibody response. In the studies reported in this paper, we show that the response which is elicited is protective.
Peter C. Giardina +3 more
openaire +3 more sources
Use of pneumococcal polysaccharide vaccines: no simple answers.
Journal of Infection, 2003Control of pneumococcal disease by vaccination with capsular polysaccharide has been investigated and promoted with variable enthusiasm for the past 90 years.
N. French
semanticscholar +1 more source
Haemophilus b polysaccharide vaccine.
JAMA, 1989To the Editor. — The Sept 9 issue ofThe Journalhighlighted the continuing controversy regarding the efficacy of the Haemophilus b polysaccharide vaccine. While the majority of studies cite a vaccine efficacy of 44% to 90%, 1-3 the case-control study from Minnesota raised questions not only regarding efficacy but also about possible negative effects of
F. Bruce Coles +2 more
openaire +3 more sources
Australian and New Zealand Journal of Medicine, 1979
Polyvalent pneumococcal polysaccharide vaccines have been shown to be safe, immunogenic and efficacious and are becoming available for use in patients at high risk of developing pneumococcal infections.
R. Douglas, I. Riley
semanticscholar +1 more source
Polyvalent pneumococcal polysaccharide vaccines have been shown to be safe, immunogenic and efficacious and are becoming available for use in patients at high risk of developing pneumococcal infections.
R. Douglas, I. Riley
semanticscholar +1 more source
Capsular Polysaccharides as Human Vaccines
1983Publisher Summary This chapter discusses the use of capsular polysaccharides as human vaccines. Vaccination has proved to be one of the most useful scientific developments in the control and eradication of human disease. Early vaccines were based on whole-organism preparations or on protein toxins isolated from different bacteria.
openaire +4 more sources
Capsular polysaccharide vaccines today
Infection, 1984Polysaccharide (PS) vaccines are a relatively new class of antibacterial vaccines that have special advantages but also special problems related to their character. Several of them have proven very effective in preventing bacteremic infections caused by encapsulated bacteria such as meningococci, pneumococci and Haemophilus influenzae type b ...
openaire +2 more sources